Delivery Order SPE2DB22D3501-SPE2DB25FWX68
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Entecavir 0.5 mg tablets in quantities of 30 units. This contract, valued at $2,631.62, represents a firm fixed price delivery order with no set-aside designation, indicating competitive award. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, with an ultimate completion date of July 23, 2025. This delivery order is...
- The Defense Logistics Agency awarded a $1,996.61 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Entecavir 0.5 mg tablets (30-count units). This is a firm fixed-price delivery order with an ultimate completion date of August 12, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, consistent with AmerisourceBergen's typical federal procurement profile....
- The Defense Logistics Agency awarded a delivery order valued at $1,202.28 to AmerisourceBergen Drug Corp for the supply of Entecavir 0.5 mg tablets (30-count) on August 11, 2025, with an ultimate completion date of August 12, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending...
- The Defense Logistics Agency awarded a delivery order valued at $5,583.57 to AmerisourceBergen Drug Corp for the supply of Entecavir 0.5 mg tablets (30-count units) on August 14, 2025, with completion scheduled for August 15, 2025. This firm fixed price delivery order was competitively awarded without set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement supporting federal medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Entecavir 0.5 mg tablets (30-count packaging) with a ceiling value of $1,650.08 under a firm fixed price contract type. The award was made on August 18, 2025, with an ultimate completion date of August 19, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, for the supply of Entecavir 0.5 mg tablets in a quantity of 30 units. This firm fixed price delivery order, valued at $2,881.89, was competitively awarded without set-aside designation and is scheduled for completion by August 4, 2025. The contract leverages AmerisourceBergen's significant Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Entecavir 0.5 mg tablets (30-count units) under a firm fixed-price contract with a ceiling value of $1,142.56. The order was competitively awarded without set-aside restrictions and is scheduled for completion by August 6, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform fulfillment from its corporate office location. This delivery order represents a child...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Entecavir 0.5 mg tablets (30-count package) with a ceiling value of $1,337.46. This is a firm fixed-price delivery order with an ultimate completion date of August 5, 2025, to be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award was not designated as a set-aside contract, indicating it was competitively awarded through open...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract valued at $1,532.79 to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the provision of 4,564,150,864 units of the prescription medication Entecavir 0.5 mg tablets. This delivery order is a part of a larger indefinite delivery contract (IDC) valued at up to $999,999,999.00 that AmerisourceBergen Drug Corp holds with DLA. The IDC serves as the primary contract vehicle for...
- This federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical was issued to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,630.72 firm-fixed-price delivery order is for the supply of Entecavir 0.5 mg tablets. The contract has an ultimate completion date of June 3, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FWX68Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Entecavir 0.5 mg tablets (30-count units) with a ceiling value of $6,742.70 and a completion date of August 19, 2025. This competitive, non-set-aside delivery order utilizes firm fixed pricing and is being fulfilled from the vendor's location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999 and extends through December 2026. This prime contract vehicle serves as a comprehensive global pharmaceutical support mechanism enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal medical procurement vendor that supplies medications, vaccines, medical devices, and healthcare commodities across multiple therapeutic domains to military and veteran healthcare systems. The company's existing federal contract portfolio demonstrates its capability to fulfill diverse pharmaceutical needs through competitive procurement, with delivery orders ranging significantly in value. The DLA's planned Pharmaceutical Prime Vendor Global Program Generation V contracts, anticipated to involve multiple regional awards with at least three contractors, indicates the agency's strategic approach to ensuring robust pharmaceutical supply chains across the Defense Health System.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.7k | 8/18/25 |